Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer

Area of Science:

• Oncology
• Urology
• Cancer Research

Background:

• Neuroendocrine prostate cancer (NEPC) is an aggressive malignancy, often arising de novo or as castration-resistant prostate cancer.
• First-line platinum-based chemotherapy offers initial efficacy but is followed by significant clinical challenges due to limited response duration and lack of established second-line treatments.

Purpose of the Study:

• To review the current landscape of second-line therapeutic options for neuroendocrine prostate cancer.
• To evaluate the efficacy and outcomes associated with existing and emerging treatments for NEPC.

Main Methods:

• A comprehensive literature search was performed using PubMed and Web of Science databases.
• A total of 13 relevant articles, including prospective and retrospective studies, were included in this systematic review.

Main Results:

• Second-line platinum-based chemotherapy (etoposide or docetaxel) demonstrated unfavorable outcomes with progression-free survival of 3 months or less.
• Agents like amrubicin and irinotecan showed modest efficacy, with response durations under 6 months.
• Poly (ADP-ribose) polymerase (PARP) inhibitors may benefit NEPC patients with homologous recombination repair gene alterations.

Conclusions:

• Current second-line therapies for NEPC offer limited clinical benefit, highlighting an unmet need for effective treatments.
• Ongoing clinical trials are exploring novel agents such as immune checkpoint inhibitors, molecularly targeted therapies, and PARP inhibitors.
• Increased recognition and biopsy of NEPC are expected to raise patient numbers, emphasizing the critical need for further research and development of innovative treatment strategies.